Genmab A/S has expanded its antibody repertoire under a new research and collaboration agreement with CureVac AG to produce antibody therapeutics for cancer that have been developed using messenger RNA (mRNA) technology. The agreement includes an upfront payment of $10 million for the first product and a €20 million equity investment in CureVac, as well as options on three other programmes. The deal was announced on 19 December 2019.
